Αρχική World News FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma World News FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Από Ogkologos - 19 Οκτωβρίου, 2026 311 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results of the RASolute 302 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Says Breast Implant Cancer Risk Is Not Enough to Warrant... 3 Μαΐου, 2019 Cancer Research UK report highlights stark cancer inequalities across Scotland 28 Νοεμβρίου, 2022 Study Suggests Watching Disney Movies May Improve Quality of Life for... 26 Μαΐου, 2020 Genetic Testing for Bladder Cancer: What People With Cancer and Their... 23 Μαρτίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Olivia Newton-John Puts On Iconic ‘Grease’ Costume And Talks About Cancer... What to Know About Treatment Options Before and After Surgery for... Μελάνωμα και καλοκαίρι. Πώς να προφυλαχθείτε Can Cancer Prevention Be Better Integrated into Primary Care?
